INmune Bio, Inc. (INMB)
1.21
-0.01
(-0.82%)
USD |
NASDAQ |
Jun 10, 16:00
1.20
-0.01
(-0.83%)
Pre-Market: 08:58
INmune Bio Total Liabilities (Quarterly) : 6.194M for March 31, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.194M |
| December 31, 2025 | 8.827M |
| September 30, 2025 | 7.98M |
| June 30, 2025 | 8.817M |
| March 31, 2025 | 8.128M |
| December 31, 2024 | 7.465M |
| September 30, 2024 | 14.11M |
| June 30, 2024 | 15.37M |
| March 31, 2024 | 17.81M |
| December 31, 2023 | 18.86M |
| September 30, 2023 | 17.97M |
| June 30, 2023 | 19.07M |
| March 31, 2023 | 18.68M |
| December 31, 2022 | 21.69M |
| September 30, 2022 | 20.09M |
| June 30, 2022 | 17.88M |
| March 31, 2022 | 18.71M |
| December 31, 2021 | 19.72M |
| September 30, 2021 | 19.42M |
| Date | Value |
|---|---|
| June 30, 2021 | 17.47M |
| March 31, 2021 | 2.312M |
| December 31, 2020 | 1.902M |
| September 30, 2020 | 1.610M |
| June 30, 2020 | 1.363M |
| March 31, 2020 | 1.271M |
| December 31, 2019 | 0.8605M |
| September 30, 2019 | 0.687M |
| June 30, 2019 | 0.6927M |
| March 31, 2019 | 0.7809M |
| December 31, 2018 | 0.8238M |
| September 30, 2018 | 0.2114M |
| June 30, 2018 | 0.1953M |
| March 31, 2018 | 0.1964M |
| December 31, 2017 | 0.3097M |
| September 30, 2017 | 0.2415M |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | 0.6008M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Sangamo Therapeutics, Inc. | 78.92M |
| Arrowhead Pharmaceuticals, Inc. | 1.669B |
| Oncolytics Biotech, Inc. | 13.29M |
| Sarepta Therapeutics, Inc. | 1.674B |
| Anixa Biosciences, Inc. | 1.387M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 25.82M |
| Shareholders Equity (Quarterly) | 19.62M |
| Debt to Equity Ratio | 0.0769 |
| Current Ratio | 4.236 |
| Net Debt Paydown Yield | -0.75% |